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Abstract. Previous studies have detected a higher level of 
ferritin in patients with hepatocellular carcinoma (HCC), but 
a potential causal association between serum ferritin level 
and hepatocarcinogenesis remains to be clarified. Using 
a well-established prospective cohort and longitudinally 
collected serial blood samples, the association between 
baseline ferritin levels and HCC risk were evaluated in 
1,152 patients infected with hepatitis B virus (HBV), a major 
risk factor for HCC. The association was assessed by Cox 
proportional hazards regression model using univariate 
and multivariate analyses and longitudinal analysis. It was 
demonstrated that HBV patients who developed HCC had 
a significantly higher baseline ferritin level than those who 
remained cancer-free (188.00 vs. 108.00 ng/ml, P<0.0001). 
The patients with a high ferritin level (≥200 ng/ml) had 
2.43-fold increased risk of HCC compared to those with 
lower ferritin levels [hazard ratio (HR), 2.43; 95% confidence 
interval, 1.63‑3.63]. A significant trend of increasing HRs 
along with elevated ferritin levels was observed (P for trend 
<0.0001). The association was still significant after multivar-
iate adjustment. Incorporating ferritin into the α-fetoprotein 
(AFP) model significantly improved the performance of 
HCC prediction (the area under the curve from 0.74 to 0.77, 
P=0.003). Longitudinal analysis showed that the average 
ferritin level in HBV patients who developed HCC was 
persistently higher than in those who were cancer-free during 
follow-up. HCC risk reached a peak at approximately the 
fifth year after baseline ferritin detection. Moreover, strati-
fied analyses showed that the association was noted in both 
males and females, and was prominent in patients with a low 
AFP value. In short, serum ferritin level could independently 
predict the risk of HBV-related HCC and may have a comple-
mentary role in AFP-based HCC diagnosis. Future studies 
are warranted to validate these findings and test its clinical 
applicability in HCC prevention and management.
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause 
of cancer-related death worldwide and a major cause of death 
in patients with cirrhosis (1). By the time HCC is detected, 
it has often reached an advanced stage for which there is no 
curative treatment. In order to identify HCC earlier, efforts 
have focused on patients with chronic hepatitis B virus (HBV) 
infection, which affects 350 million persons worldwide and 
is the most common risk factor for HCC (1). The ability to 
identify patients who are at high risk for HBV-related HCC 
would benefit the prevention and early detection of HCC.
Recent studies have indicated that measurement of 
ferritin, the major cellular storage protein for iron (2), may 
allow for such early detection of HCC. In vitro studies showed 
that iron induced increased ferritin synthesis by hepatoma 
cell lines and enhanced tumor cell growth (3,4). Elevated 
serum ferritin was also associated with inflammation and 
liver diseases (2,5,6). Moreover, ferritin that is synthesized 
by tumor cells may exert adverse effects on host immune 
responses and defense mechanisms (3). Population studies 
have clearly documented that HCC patients have a higher 
level of ferritin than healthy subjects or patients with other 
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liver diseases (7-9), but retrospective studies cannot clarify 
whether the increased level is the cause or consequence of 
HCC because ferritin is also produced by the tumor cells. 
Meanwhile, very few studies have prospectively evaluated 
the relationship between serum ferritin level and HCC risk in 
HBV patients. A nested case-control study in Taiwan reported 
that 192 men who developed primary HCC and/or died of 
cancer had higher mean serum ferritin at the start of the study, 
compared to those who were alive and free of HCC at the 
date the case failed (developed HCC or died of cancer) (10). A 
study conducted in Korean patients with chronic hepatitis B 
and cirrhosis reported that males with sustained high serum 
ferritin levels had a high chance of developing HCC (5); 
however, in this study, only 162 patients (46 females) were 
included, ferritin levels were merely measured within the 
first 8 months, and covariates were not considered. We 
designed a prospective cohort study with more than 10-year 
follow-up and longitudinally collected serial blood samples 
from HBV-infected patients in order to further clarify the 
association between baseline ferritin levels and HCC risk in 
HBV-infected patients, and to explore the dynamic change of 
ferritin level and HCC risk over time.
Subjects and methods
Subjects. The subjects were identified from an ongoing 
clinic-based patient cohort that was established in 1988 (11). 
The patients were recruited when they visited the Liver 
Disease Prevention Center at Thomas Jefferson University 
Hospital for the treatment of chronic HBV or HCV infec-
tion and liver diseases including cirrhosis, fibrosis, and/or 
HCC. There was no restriction on age, gender, and disease 
etiology for patient recruitment. Majority (>90%) of the 
patients in the cohort were of Korean ancestry. The patients 
included in the current study met the following criteria: i) To 
eliminate the confounding effects from disease etiologies, 
patients had HBV infection only, without concomitant infec-
tion with HCV, HIV, or other viruses; ii) to minimize the 
confounding effects of population stratification and ethnic 
origin, patients were Korean Americans; iii)  patients had 
developed primary rather than secondary HCC during 
follow-up; iv) patients were followed for at least 1 year, and 
during which time HCC did not develop; v) patients had both 
ferritin and α-fetoprotein (AFP) values measured simultane-
ously at study entry; and vi) major demographic and clinical 
data were available, such as date of HCC diagnosis. This 
study was approved by the Institutional Review Board of 
Thomas Jefferson University. Written informed consent was 
obtained from each patient.
Data collection. Demographic and clinical data were obtained 
by reviewing medical charts and/or consulting the treating 
physicians. Related variables included age, gender, ethnicity, 
smoking status, drinking status, cirrhosis status, and family 
history of cancer. Ever smokers and drinkers were defined as 
previously (12). Liver cirrhosis and HCC were diagnosed by 
the combination of clinical diagnosis and imaging techniques 
(e.g., ultrasound, computed tomography, magnetic resonance 
imaging), complemented by blood markers (e.g., AFP) (11). 
Ferritin levels for each patient were detected at the initial visit, 
as well as at follow-up visits, with the intervals determined by 
the treating physicians.
Statistical analysis. SAS (version 9.4; SAS Institute, Inc., 
Cary, NC, USA) and Stata (version 12.0; StataCorp LP, 
College Station, TX, USA) software packages were used 
for data analyses. All statistical tests were two-sided, and 
a P-value of less than 0.05 was considered as the threshold 
of statistical significance. The clinical endpoint analyzed in 
this study was HCC development. Time to HCC development 
was defined as the date from the study entry to the date of 
HCC diagnosis or last follow-up. Patients who were free of 
HCC at the last follow-up date were censored for analysis. 
The patients were then divided into two, three, or four risk 
groups, according to the clinical cut-off of 200 ng/ml (2,13), 
or median/tertile/quartile of ferritin level in cancer-free 
HBV patients. The cumulative incidence of HCC in each risk 
group was plotted using the Nelson-Aalen method (14) and 
compared using the log-rank test. The association between 
ferritin level and HCC risk was evaluated using univariate 
and multivariate Cox proportional hazards regression model, 
adjusting for age, gender, smoking status, drinking status, 
cirrhosis, and family history of cancer. Because all patients 
received standard-of-care treatment based on the AASLD 
guidelines and adjustment of treatment did not affect the 
results, we did not include treatment in the multivariate 
adjustment in the current study. The proportional hazards 
assumption was validated using the test based on Schoenfeld 
residuals. The significance and strength of association 
was presented as hazard ratio (HR) with 95% confidence 
interval (CI). Discrimination accuracy for predicting the 
development of HCC was evaluated by constructing receiver 
operating characteristic (ROC) curves and calculating the 
area under the curve (AUC). Interactions between ferritin 
levels and other variables on HCC risk were assessed by 
adding an interaction term into the Cox regression model. 
Time-dependent effect of ferritin levels on HCC risk was 
analyzed using the flexible parametric survival model with 
a restricted cubic spline function (15). To better understand 
the dynamic change of ferritin during follow-up, we selected 
a sub-cohort of 461 patients whose ferritin level was detected 
≥3 times since the initial visit. The longitudinal trends of 
temporal changes in average ferritin levels were plotted by 
fitting a smoothing spline over time and compared between 
the patients who developed HCC and those who remained 
cancer-free during follow-up (16).
Results
Patient characteristics. A total of 1,152 HBV patients were 
included in this study, and among them, 96 (8.3%) patients 
developed early-stage HCC during follow-up. The patient 
characteristics are summarized in Table I. The mean age 
of patients at enrollment was 43.6 years old (age range: 
18.7-77.8 years). The majority of patients were males (66.1%, 
sex ratio: 1.95), never smokers (59.7%), never drinkers (56.1%), 
without cirrhosis (71.8%) or a family history of cancer (67.4%). 
As expected, HCC risk was significantly increased among 
older patients (HR=2.23, 95% CI, 1.36-3.65), males (HR=1.88, 
95% CI, 1.01-3.47), ever smokers (HR=2.47, 95% CI, 1.39-4.38), 
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cirrhotic patients (HR=7.62, 95% CI, 4.53-12.83), and patients 
with a high AFP value (HR=2.75, 95% CI, 1.78-4.25). Although 
increased HCC risk was observed in ever drinkers and patients 
with a family history of cancer in the univariate analyses, the 
associations were not statistically significant after adjustment 
for covariates.
Association between ferritin level and HCC risk. HBV 
patients who developed HCC had a significantly higher 
ferritin level [median 188.00 ng/ml, interquartile range (IQR) 
119.50-299.76 ng/ml] than those who remained cancer-free 
(median 108.00 ng/ml, IQR 53.10-204.95 ng/ml, P<0.0001). We 
then divided HBV patients into different risk groups according 
to the clinical cut-off or percentile cut-offs. As shown in 
Fig. 1, the cumulative HCC incidence was significantly higher 
in patients with a high ferritin level than in those with a low 
ferritin level, no matter which kind of cut-offs were used (all 
log-rank P<0.0001). Compared to the patients with a ferritin 
level less than 200 ng/ml, the patients with a high ferritin level 
(≥200 ng/ml) had 2.43-fold increased risk of HCC (HR=2.43, 
95% CI, 1.63‑3.63, Table II). The association was still significant 
after adjusting for age, gender, smoking status, drinking status, 
and family history of cancer (HR=1.76, 95% CI, 1.16-2.65) 
and became borderline significant when cirrhosis and AFP 
were further added to multivariate adjustment (HR=1.45, 
95% CI, 0.96-2.19). When patients were categorized according 
to median/tertile/quartile cutoffs, the association between 
ferritin and HCC risk was consistently observed in univariate 
and multivariate analyses (Table II). Moreover, a trend of 
increasing HRs along with elevated ferritin levels was noted 
(P for trend <0.0001 in univariate analyses and <0.01 after 
multivariate adjustment, Table II).
Prediction performance of ferritin combined with AFP. 
AFP is a commonly used tumor marker in HCC diagnosis, 
although with a non-optimal discrimination accuracy (17). We 
Table I. Characteristics of the study population.
 Univariate analysis Multivariate analysisa
 ----------------------------------------------------------- -----------------------------------------------------------
 Total HBV HBV patients who HR  HR
Variables patients, no. (%) developed HCC, no. (%)  (95% CI) P-value  (95% CI) P-value
Age (years), 43.61 (11.75) 50.97 (10.36) 1.07 (1.05-1.08) <0.0001c 1.05 (1.03-1.07) <0.0001c
mean (SD) 
  <43 550 (47.7) 22 (22.9) 1.00  1.00 
  ≥43 602 (52.3) 74 (77.1) 3.48 (2.16‑5.61) <0.0001c 2.23 (1.36-3.65) 0.0014c
Gender      
  Female 391 (33.9) 15 (15.6) 1.00  1.00 
  Male 761 (66.1) 81 (84.4) 2.81 (1.62‑4.88) 0.0002c 1.88 (1.01-3.47) 0.0450c
Smoking status      
  Never 688 (59.7) 35 (36.5) 1.00  1.00 
  Ever 382 (33.2) 49 (51.0) 2.61 (1.69-4.03) <0.0001c 2.47 (1.39-4.38) 0.0021c
  Unknown 82 (7.1) 12 (12.5) 2.84 (1.47-5.47) 0.0019 12.43 (2.92-52.97) 0.0007
Drinking status      
  Never 646 (56.1) 41 (42.7) 1.00  1.00 
  Ever 425 (36.9) 45 (46.9) 1.72 (1.12-2.62) 0.0123c 0.67 (0.38-1.16) 0.1527
  Unknown 81 (7.0) 10 (10.4) 1.90 (0.95-3.79) 0.0693 0.15 (0.03-0.71) 0.0171
Cirrhosis      
  No 827 (71.8) 19 (19.8) 1.00  1.00 
  Yes 325 (28.2) 77 (80.2) 12.25 (7.41-20.25) <0.0001c 7.62 (4.53-12.83) <0.0001c
Family history
of cancer
  No 776 (67.4) 57 (59.4) 1.00  1.00 
  Yes 376 (32.6) 39 (40.6) 1.50 (1.00-2.25) 0.0523 1.21 (0.80-1.84) 0.3657
AFP (ng/ml),  3.10 (2.00-6.40) 10.86 (5.15-47.05) 1.62 (1.50-1.76)b <0.0001b,c 1.51 (1.36-1.67)b <0.0001b,c
median (IQR)
  <20 1015 (88.1) 59 (61.5) 1.00  1.00
  ≥20 137 (11.9) 37 (38.5) 5.39 (3.57‑8.13) <0.0001c 2.75 (1.78-4.25) <0.0001c
HCC, hepatocellular carcinoma; SD, standard deviation; IQR, interquartile range; AFP, α‑fetoprotein; HR, hazard ratio; CI, confidence interval. 
aAdjusted for age, gender, smoking status, drinking status, family history of cancer, and cirrhosis, where appropriate. bAfter natural log trans-
formation. cP<0.05.
BIAN et al:  FERRITIN LEVEL AND HCC RISK3502
then investigated whether incorporating ferritin into the AFP 
prediction model could improve the performance of predicting 
HCC. The results showed that compared to the performance 
in the model with AFP values, the prediction performance 
significantly increased in the model in combination of ferritin 
and AFP levels (AUC from 0.74 to 0.77, P=0.003; Fig. 2).
Time‑dependent effect and dynamic change of ferritin level. 
Time-dependent effect of ferritin level on HCC risk was 
assessed using the flexible parametric model. As shown in 
Fig. 3A, after the initial visit, HCC risk significantly increased 
in the first 5 years, reached a peak at approximately the fifth 
year, and kept stable after 10 years. To evaluate dynamic 
change of ferritin, we also selected a sub-cohort of 461 patients 
with 4309 detections of ferritin at both baseline and follow-up 
visits, and depicted the longitudinal trend of average ferritin 
values by fitting a smoothing spline over time (Fig. 3B). 
The average ferritin level in HBV patients who developed 
HCC (n=50) was persistently higher than in those remaining 
cancer-free (n=411).
Stratified and joint effects of ferritin level on HCC risk. We 
stratified the main effect analysis according to patients' char-
acteristics. In the univariate analyses, the association of ferritin 
level with HCC risk was significant in both strata divided by 
age, gender, drinking status, and family history of cancer, and 
only evident in ever smokers (P=0.0233), non-cirrhotic patients 
(P=0.0155), and patients with a AFP value less than 20 ng/ml 
(P=0.0004; Table III). After multivariate adjustment, we only 
observed a borderline significant association in older patients 
(P=0.0940) and patients with a low AFP value (P=0.0837).
Figure 1. Cumulative incidence of HBV-related HCC. The cumulative incidence of HCC was plotted using the Nelson-Aalen method by analyzing Ferritin as a 
categorical variable by clinical cut-off of (A) 200 ng/ml, (B) median, (C) tertile, and (D) quartile cut-offs. HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
Figure 2. Receiver operating characteristic curves for assessment of predic-
tion performance of HCC. The AUC was compared between the AFP models 
without and with ferritin levels. AUC, area under the curve; HCC, hepatocel-
lular carcinoma.
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Because the clinical normal range differed between 
females and males (13) and because we detected a joint 
effect between ferritin level and gender on HCC risk (P for 
interaction=0.0087), we further evaluated gender‑specific 
effect and compared the cumulative incidence in females 
and males. As expected, ferritin levels were much higher in 
males than in females (median 160 ng/ml vs. 50.40 ng/ml, 
P<0.0001). Both female and male HBV patients who devel-
oped HCC had significantly higher ferritin levels compared 
to those who were still cancer-free (134 vs. 48.95 ng/ml, 
P=0.0003 in females; 188.90 vs. 154.80 ng/ml, P=0.0025 in 
males, Table IV). The significantly increased cumulative inci-
dence was observed in both female and male patients with a 
high ferritin level when gender‑specific clinical cut‑offs were 
used (Fig. 4A and B).
We also detected a joint effect between ferritin and 
AFP level on HCC risk (P for interaction=0.0036). We then 
compared ferritin level and cumulative incidence in patients 
with a low or high AFP value. We noticed that in patients 
with a low AFP value (<20 ng/ml), the HBV patients who 
developed HCC had a significantly higher level of ferritin 
than those who remained cancer-free (178 vs. 103.25 ng/ml, 
P<0.0001; Table V); however, in patients with a high AFP value 
(≥20 ng/ml), the ferritin level in the HCC patients was slightly 
lower than that in the non-HCC patients (230 vs. 283 ng/ml), 
but the difference was not statistically significant. Similarly, 
significantly increased cumulative incidence of HCC with 
elevated ferritin level was observed in patients with a low AFP 
value (Fig. 4C and D).
Discussion
Serum ferritin is a widely available and easily measured 
biochemical parameter in clinics. Previous studies detected a 
higher level of ferritin in HCC patients; however, these studies 
did not reveal whether there was a causal association between 
serum ferritin level and hepatocarcinogenesis in HBV infected 
patients. In the current study based on a well-established 
prospective cohort, we demonstrated that baseline ferritin 
level could independently predict the risk of HBV-related 
HCC, especially in the first 10 years of follow‑up. Moreover, 
the association between ferritin level and HCC risk was noted 
in both males and females, and was prominent in patients with 
a low AFP value.
The tumor enhancing effect of iron has been well docu-
mented (18,19). Accumulating evidence has indicated that an 
increased iron level predisposes a patient to infection, induces 
oxidative stress, modifies the immune system, and facilitates 
the growth of tumor cells (2,5,20,21). Furthermore, anti-
tumor effect of iron depletion by deferoxamine was observed 
in nude mice bearing human HCC (22). As an iron storage 
protein, ferritin makes iron available for critical cellular 
processes while protecting lipids, DNA, and proteins from 
the potentially toxic effects of iron (23). Serum ferritin is an 
inexpensive biomarker in identifying clinically significant 
iron overload (23). Elevated ferritin concentrations could 
also be observed in inflammatory processes, autoimmune 
diseases, neurodegenerative, metabolic syndrome, and malig-
nant diseases (23). In addition to the amount synthesized by 
tumor cells, ferritin is also released into the circulation by 
damaged hepatocytes in liver diseases. Cirrhosis is almost 
always present when HCC is diagnosed and progressive 
hepatic iron loading develops in one-third of patients with 
long-standing liver cirrhosis (21); however, previous studies 
failed to clarify whether ferritin is an independent predictor 
of HCC or acts indirectly through coexisting cirrhosis. 
A recent animal model of dietary iron overload reported 
iron-free preneoplastic nodules and HCC developed in the 
absence of fibrosis or cirrhosis, suggesting that ionic iron 
may also be directly hepatocarcinogenic (24,25). In the 
current study, which was conducted in chronic HBV infected 
patients, we demonstrated the association between ferritin 
and HCC risk that was independent of other liver diseases 
including cirrhosis (Table II).
It is well known that the average ferritin level in males is 
much higher than in females, thus a gender‑specific cut‑off is 
Figure 3. Time-dependent effect and dynamic change of Ferritin level. (A) Time-dependent effect of Ferritin level on HCC risk, red solid line represents HR, 
shaded area shows 95% confidence interval, blue dash line indicates a reference HR of 1; (B) Longitudinal trend of average Ferritin level in the patients who 
developed HCC (red solid line) and those who were cancer‑free (blue dash line), grey lines indicate individual profiles for all subjects. HR, hazard ratio; HCC, 
hepatocellular carcinoma.
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often suggested in clinics (2,13,26). A recent study reported 
an independent predicting value of serum ferritin in the 
development of HCV-related HCC, and this association 
was only observed in male patients (27). Previous studies 
Table III. Associations between Ferritin level and HCC risk stratified by patients' characteristics.
  Univariate analysis Multivariate analysisa
 Ferritin values HCC/total ---------------------------------------------------------- ------------------------------------------------------
Variable (ng/ml) patients (N) HR (95% CI) P-value HR (95% CI) P-value
Age (years)      
  <43 <200  12/416 1  1 
 ≥200  10/134 2.74 (1.18‑6.33) 0.0188b 1.70 (0.70-4.17) 0.2430
  ≥43 <200  39/416 1  1 
 ≥200  35/186 2.11 (1.34‑3.33) 0.0013b 1.50 (0.93-2.40) 0.0940
  P for interaction    0.6144  0.9970
Gender      
  Female <200  9/353 1  1 
 ≥200  6/38 7.29 (2.59‑20.51) 0.0002b 1.25 (0.29-5.45) 0.7695
  Male <200  42/479 1  1 
 ≥200  39/282 1.64 (1.06‑2.53) 0.0269b 1.45 (0.93-2.27) 0.1040
  P for interaction    0.0087b  0.9203
Smoking status      
  Never <200  23/533 1  1 
 ≥200  12/155 1.88 (0.94‑3.78) 0.0758 1.12 (0.54‑2.33) 0.7679
  Ever <200  23/236 1  1 
 ≥200  26/146 1.92 (1.09‑3.36) 0.0233b 1.48 (0.81-2.71) 0.2064
  P for interaction    0.9982  0.5633
Drinking status      
  Never <200  26/505 1  1 
 ≥200  15/141 2.23 (1.18‑4.21) 0.0136b 1.14 (0.58-2.24) 0.7121
  Ever <200  21/264 1  1 
 ≥200  24/161 1.93 (1.08‑3.47) 0.0275b 1.41 (0.76-2.64) 0.2774
  P for interaction    0.7706  0.8010
Cirrhosis      
  No <200  10/639 1  1 
 ≥200  9/196 3.04 (1.24‑7.49) 0.0155b 1.27 (0.46-3.52) 0.6515
  Yes <200  41/193 1  1 
 ≥200  36/124 1.43 (0.91‑2.24) 0.1176 1.27 (0.80‑2.03) 0.3078
  P for interaction    0.1410  0.5747
Family history of cancer      
  No <200  30/575 1  1 
 ≥200  27/201 2.70 (1.61‑4.54) 0.0002b 1.53 (0.89-2.65) 0.1263
  Yes <200  21/257 1  1 
 ≥200  18/119 1.95 (1.04‑3.67) 0.0375b 1.25 (0.63-2.49) 0.5233
  P for interaction    0.4255  0.8123
AFP (ng/ml)      
  <20 <200  34/778 1  1 
 ≥200  25/237 2.55 (1.52‑4.28) 0.0004b 1.61 (0.94-2.77) 0.0837
  ≥20 <200  17/54 1  1 
 ≥200 20/83 0.72 (0.38‑1.38) 0.3194 0.75 (0.38‑1.46) 0.3954
  P for interaction    0.0036b  0.0583b
 
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein. aAdjusted for age, gender, smoking status, 
drinking status, family history of cancer, cirrhosis, and AFP level, where appropriate. bP<0.05.
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conducted in HBV patients also identified increased HCC 
risk in male patients with a high level of ferritin. But these 
studies were either conducted in males alone (10) or involved 
a small number of female patients (5). Our present study with 
761 males and 391 females demonstrated that the association 
between ferritin level and HCC risk was observed in both 
Table IV. Ferritin levels by gender.
 Females (n=391) Males (n=761)
 ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
Variables Non-HCC (n=376) HCC (n=15) P-value Non-HCC (n=680) HCC (n=81) P-value
Ferritin (ng/ml),  48.95 134.00 0.0003a 154.80 188.90 0.0025a
median (IQR) (25.60-96.95) (96.00-446.00)  (95.00-256.35) (124.00-296.52)
HCC, hepatocellular carcinoma; IQR, interquartile range. aP<0.05.
Table V. Ferritin levels by AFP level.
 AFP <20 ng/ml (n=1,015) AFP ≥20 ng/ml (n=137)
 ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
Variables Non-HCC (n=956) HCC (n=59) P-value Non-HCC (n=100) HCC (n=37) P-value
Ferritin (ng/ml), 103.25 178.00 <0.0001a 283.00 230.00 0.38750a
median (IQR) (50.00-187.25) (119.00-253.30)  (123.20-619.00) (120.00-495.00)
AFP, α-fetoprotein; HCC, hepatocellular carcinoma; IQR, interquartile range. aP<0.05.
Figure 4. Cumulative incidence of HBV‑related HCC stratified by gender and AFP value. The cumulative incidence of HCC was compared between patients 
with a low and high Ferritin level in (A) females, (B) males, (C) patients with a low AFP value, or (D) patients with a high AFP value. HBV, hepatitis B virus; 
HCC, hepatocellular carcinoma.
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males and females, even when males or females were strati-
fied into different risk groups by a gender‑specific cut‑off of 
ferritin (Fig. 3). It is unclear whether the inconsistent finding 
of ferritin effect on HBV patients compared to HCV patients 
signifies that hepatocarcinogenesis differs in patients with 
different disease etiologies. It would be worthwhile to 
conduct additional studies to validate our finding and clarify 
gender‑specific effects.
AFP is a widely recognized tumor marker for the diagnosis 
of HCC. However, there have been false-positive results for 
HCC detection, as elevated AFP also occurs in chronic liver 
disease and other malignancies than HCC; false-negative 
results were reported as well, as not all HCCs secrete 
AFP (17,28,29). Our results showed that the performance of 
HCC prediction significantly improved after incorporating 
ferritin into the AFP prediction model (Fig. 2), suggesting a 
complementary role of ferritin in prediction of HCC devel-
opment. Adult hepatocytes re-express AFP mainly through 
mechanisms including hepatocyte regeneration, and oxidative 
stress induced DNA damage (30). Noritake et al (31) reported 
that iron reduction by therapeutic phlebotomy could reduce 
the serum AFP in HCV patients, which probably mediated by 
the amelioration of enhanced hepatic iron-mediated oxidative 
stress. Although the biological mechanisms underlying the 
combined effect of AFP and Ferritin on HCC development are 
still needed to be further investigated, the present findings in 
our study demonstrated the potential of using these two serum 
markers for the joint diagnosis of HCC. Nevertheless, it should 
be noted that after adding ferritin to the model, the diagnostic 
power was still moderate, albeit slightly increased. Therefore, 
it would be worthwhile to study whether a model including 
more risk factors, as well as novel molecular markers could 
further improve the diagnostic performance. In addition, in the 
stratification analyses, we found that the association of ferritin 
level with HCC risk was more evident in patients with a AFP 
value less than 20 ng/ml. Our result was consistent with the 
finding of Zhou et al (32) who suggested that serum ferritin 
estimation may be helpful in detection of HCC without elevated 
AFP, and further supported the complementary information 
from ferritin to AFP-based HCC diagnosis. Nevertheless, due 
to decreased sample size in each stratum, especially in the 
patients with a high level of AFP, it should be cautious when 
we explained the detected interaction between ferritin and 
AFP, as well as, the failure in identifying significant difference 
in ferritin levels between HCC and non-HCC patients when 
the comparison was conducted in those with elevated AFP.
Our study was based on a large-scale and homogenous 
cohort of Korean patients with chronic HBV infection, so the 
confounding effects of patient ethnicity and disease etiology 
have been eliminated. We only included patients who were 
followed for at least 1 year, and during which time HCC did not 
develop (1-year exclusion window). This criterion ensured that 
all of the patients were free of HCC at study entry. Therefore, 
the increased baseline ferritin level was more likely linked to 
the development of HCC rather than the release from existing 
tumor cells. In order to minimize the confounding effect of 
any patient who had undiagnosed HCC at baseline sample 
collection, we further restricted the analyses to a sub-cohort of 
patients with a 2-year exclusion window, that is, only included 
the patients who were followed for at least 2 years and had 
not developed HCC within these 2 years. The result from this 
sub-cohort analysis (HR=2.76, 95% CI, 1.60-4.78; adjusted 
HR=2.23, 95% CI, 1.25-3.97) was very similar to that from 
the analysis based on the population with 1-year exclusion 
window (HR=2.43, 95% CI, 1.63-3.63; adjusted HR=1.76, 
95% CI, 1.16-2.65, Table II), which substantiates the robust-
ness of our findings. Furthermore, ferritin is a non‑invasive, 
cost-effective, and easily obtained biomarker in clinics so that 
it can be real-time detected and repetitively monitored during 
follow-up.
Our study also has limitations. First, liver biopsy is the 
gold standard for quantifying iron, while serum ferritin 
levels do not always accurately reflect tissue iron (2,23,33). 
However, in the current study, very few patients had baseline 
serum iron concentration or transferrin saturation, and none 
of the patients had detection of tissue iron, so we are unable 
to accurately assess the relationship between ferritin, iron, 
and the development of HBV-related HCC. Second, some 
important covariates, such as HBV DNA loading and body 
mass index, which were reported to be associated with HCC 
risk and/or correlate with serum ferritin level (12,34), were not 
included in multivariate analyses due to a high percentage of 
missing values. Future studies with more complete data could 
be designed to evaluate the confounding effects from these 
covariates. Third, this study was based on the data collected 
in a single institute. Prospective studies from independent 
external cohorts are required to validate our results. Moreover, 
the generalizability of our findings to patients of other ethnici-
ties or disease etiologies is required to be assessed.
In short, our large scale cohort study indicated that serum 
ferritin could prospectively predict hepatocarcinogenesis in 
chronic HBV infected patients. Given ferritin is a non-invasive 
blood-born maker which can be easily obtained from routine 
laboratory test and be real-time monitored during follow-up, 
the clinical significance of ferritin in early diagnosis and effec-
tive management of HCC should not be overlooked.
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